HW
HRMY icon

Hancock Whitney’s Harmony Biosciences HRMY Stock Holding History

Hancock Whitney’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Sell
8,677
-8,146
-48% -$257K 0.01% 656
2026
Q1 		$526K Buy
16,823
+6,534
+64% +$214K 0.01% 555
2025
Q4 		$385K Buy
10,289
+160
+2% +$5.26K 0.01% 618
2025
Q3 		$279K Sell
10,129
-46
-0.5% -$1.58K 0.01% 684
2025
Q2 		$322K Buy
10,175
+1,347
+15% +$43.3K 0.01% 652
2025
Q1 		$293K Buy
8,828
+60
+0.7% +$2.15K 0.01% 550
2024
Q4 		$302K Sell
8,768
-468
-5% -$16.1K 0.01% 535
2024
Q3 		$369K Buy
9,236
+118
+1% +$4.14K 0.01% 494
2024
Q2 		$275K Sell
9,118
-1,429
-14% -$43K 0.01% 532
2024
Q1 		$354K Buy
+10,547
New +$339K 0.01% 510
2023
Q1 		– Sell
-4,331
Closed -$239K – 643
2022
Q4 		$239K Buy
+4,331
New +$238K 0.01% 571

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hancock Whitney's HRMY Position: Q2 2026 in Review

Hancock Whitney reduced its Harmony Biosciences (HRMY) stake by 48% in Q2 2026, selling an estimated $257K and leaving 8,677 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #656.

Hancock Whitney first reported a position in HRMY in Q4 2022 and has held it in 11 quarters since. The position peaked at $526K in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Hancock Whitney held 8,677 shares of Harmony Biosciences worth $316K as of Q2 2026.
  • Hancock Whitney sold 8,146 Harmony Biosciences shares in Q2 2026, an estimated $257K.
  • Harmony Biosciences made up 0.01% of Hancock Whitney's portfolio in Q2 2026, its #656 holding.
  • Hancock Whitney first reported a position in Harmony Biosciences in Q4 2022 and has held it in 11 quarters since.
  • Hancock Whitney's Harmony Biosciences position peaked at $526K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.